Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:10/22/2007

n patients with advanced solid tumors and in patients co-infected with HCV and HIV.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the protocol will not be approved, the risk that the company will experience delays or difficulties in enrolling patients in the study, and the risk that the results from this trial will not be consistent with the results of prior trials or pre-clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and quarterly report on Form 10-Q for the quarter ended July 31, 2007. The company cautions investors not to place undue re
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) ... Outlook 2015: Accelerating growth to the next level - ... to their offering. Domestic sales improved ... caused by the market,s reaction to the new drug ... to be healthy, as the momentum continues and improving ...
(Date:3/5/2015)...  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... to be held March 8-11, 2015, in ... Sapirstein , Chief Executive Officer, will provide an overview ... will be available to participate in one-on-one meetings with ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vwvddw/therapeutic_drug ... new report "Therapeutic Drug Monitoring - Technologies, ... This report deals with therapeutic drug ... patient care by monitoring drug levels in the ... for improving outcome. TDM is viewed as a ...
Breaking Medicine Technology:India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3ContraVir to Present at 27th Annual ROTH Conference 2Global Therapeutic Drug Monitoring Report 2015 - Technologies, Markets, and Companies Analysis 2014-2024 2
(Date:3/5/2015)... (PRWEB) March 05, 2015 The recent ... weight loss promises is alarming, with more and more ... without an actual prescription, making it easy for more ... simply take their money and endanger their health. The ... before purchasing prescription online diet pills: , 1.    Where are ...
(Date:3/5/2015)... ATLANTA, GA (PRWEB) March 05, 2015 ... networking and relationship-marketing firm, honored finalists and winners ... Southeast Executive Forum and Awards Gala at the ... Chronis, chief security officer for EarthLink, was selected ... Award winner for the ISE® Southeast Region. Pete ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Considering egg ... fertility practice, is holding an informational event ... proactively plan for future families with egg freezing. , ... Plaza, 3500 Peachtree Rd, Atlanta, GA, Time: 5:30 - ... but RSVP required. Register here ! , In ...
(Date:3/5/2015)... 05, 2015 What makes a legend? In ... it’s almost 50 years of exceptional courtroom performance, championing big ... his five decades of brilliant service, the Dallas Bar Association ... Schmidt will be honored at a luncheon on Tuesday, April ... Ross Avenue. Other award nominees for this year are Bob ...
(Date:3/5/2015)... Developers and plugin specialists of Final ... transition pack entitled TranSlice Wipe for FCPX. , “TranSlice ... ease while maintaining a professional look,” Said Christina Austin, ... time saver with transitions our users will love.” , ... screen transitions with a new style. TranSlice Wipe allows ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 2Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 4Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 2Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 3Health News:C.L. Mike Schmidt Named "Legend In Trial Law" by Dallas Bar Association 2Health News:Pixel Film Studios Released TranSlice Wipe Exclusively for Final Cut Pro X Editors 2
... has been awarded to researchers at Queen,s to help ... likely to smoke than the general population. , It ... the scientists discover improved treatments for nicotine dependence - ... death from smoking-related diseases - as well as treatments ...
... A minimally invasive treatment for a common cause of male infertility ... new study published in the August issue of Radiology. , ... ... minimally invasive treatment for a common cause of male infertility can ...
... application of a pain-relieving gel may reduce the breast ... the results of a clinical trial published in the ... have something that we know reduces discomfort with screening ... the trial,s principal investigator, Colleen Lambertz, F.N.P., a nurse ...
... removed than men, study shows , , MONDAY, July 21 (HealthDay ... with their decision, women are much more likely than men ... , The study authors noted that the gender difference might ... more social stigma and negative comments as a result of ...
... -- Researchers from Duke University, the University of Cincinnati ... hoping to find a geographical pattern to help explain ... disease amyotrophic lateral sclerosis (ALS) at twice the normal ... layering military records of troop locations onto Gulf-area maps, ...
... kill cells on organ,s surface, spare surrounding tissue ... are being recruited for a clinical trial of a ... a cancer of the lung,s lining that,s almost always ... treatment is to remove the affected lung. , "Current ...
Cached Medicine News:Health News:Grant will help patients with schizophrenia who smoke 2Health News:Minimally Invasive Treatment Improves Male Fertility 2Health News:Minimally Invasive Treatment Improves Male Fertility 3Health News:Over-the-counter anesthetic gel puts the squeeze on mammogram pain 2Health News:Women More Likely to Have Second Thoughts on Tattoos 2Health News:Women More Likely to Have Second Thoughts on Tattoos 3Health News:Researchers probe geographical ties to ALS cases among 1991 Gulf War veterans 2Health News:Researchers probe geographical ties to ALS cases among 1991 Gulf War veterans 3Health News:Lung Cancer Trial Targets Asbestos-Related Disease 2
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Green Adult. Use in 7.0 to 10mm tubes. 25/box....
Medicine Products: